000142358 001__ 142358
000142358 005__ 20240229105148.0
000142358 0247_ $$2doi$$a10.18632/oncotarget.24997
000142358 0247_ $$2pmid$$apmid:29765529
000142358 0247_ $$2pmc$$apmc:PMC5940384
000142358 037__ $$aDKFZ-2019-00134
000142358 041__ $$aeng
000142358 082__ $$a610
000142358 1001_ $$aGaiser, Timo$$b0
000142358 245__ $$aMYC gene amplification is a rare event in atypical fibroxanthoma and pleomorphic dermal sarcoma.
000142358 260__ $$a[S.l.]$$bImpact Journals LLC$$c2018
000142358 3367_ $$2DRIVER$$aarticle
000142358 3367_ $$2DataCite$$aOutput Types/Journal article
000142358 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1549528807_657
000142358 3367_ $$2BibTeX$$aARTICLE
000142358 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142358 3367_ $$00$$2EndNote$$aJournal Article
000142358 520__ $$aAtypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) are rare malignancies typically occurring in elderly patients and predominantly located in skin regions exposed to UV-light. Thus, a role of UV-radiation-induced damage for AFX and PDS tumorigenesis has been postulated. MYC gene amplification has been demonstrated as a distinctive feature of radiation-induced angiosarcoma. In order to investigate whether chronic exposure to UV-light might also lead to MYC copy number changes, 51 AFX and 24 PDS samples were retrospectively analyzed for MYC amplification by fluorescence in situ hybridization using a MYC and a CEP8 gene probe. Of the 44 analyzable AFX samples, one case showed MYC amplification (defined as a MYC/CEP8 ratio ≥2.0), whereas 13 cases demonstrated low level copy number gains (defined as MYC/CEP8 ratio ≥ 1.2-< 2.0). MYC amplification was seen in an AFX sample of extraordinary tumor thickness of 17.5 mm (vs. median 3.25 mm for all samples). Of the 24 PDS cases, five specimen demonstrated MYC low level copy number gains. Immunohistochemically, neither the AFX nor the PDS cases showed MYC protein expression. In summary, these findings rule out that MYC amplification is a major genetic driver in the process of AFX or PDS tumorigenesis. However, MYC amplification may occur as a late event during AFX development and hence might only be detectable in advanced, thick lesions.
000142358 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000142358 588__ $$aDataset connected to CrossRef, PubMed,
000142358 7001_ $$aHirsch, Daniela$$b1
000142358 7001_ $$aOrouji, Azadeh$$b2
000142358 7001_ $$aBach, Marisa$$b3
000142358 7001_ $$aKind, Peter$$b4
000142358 7001_ $$aHelbig, Doris$$b5
000142358 7001_ $$aQuaas, Alexander$$b6
000142358 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, Jochen$$b7$$udkfz
000142358 7001_ $$aMarx, Alexander$$b8
000142358 7001_ $$0P:(DE-HGF)0$$aGaiser, Maria Rita$$b9$$eLast author
000142358 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.24997$$gVol. 9, no. 30$$n30$$p21182-21189$$tOncoTarget$$v9$$x1949-2553$$y2018
000142358 909CO $$ooai:inrepo02.dkfz.de:142358$$pVDB
000142358 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142358 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142358 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142358 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142358 9141_ $$y2018
000142358 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000142358 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000142358 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000142358 9201_ $$0I:(DE-He78)G300-20160331$$kG300$$lKKE Dermatoonkologie$$x0
000142358 980__ $$ajournal
000142358 980__ $$aVDB
000142358 980__ $$aI:(DE-He78)G300-20160331
000142358 980__ $$aUNRESTRICTED